Literature DB >> 1916506

Improved prognosis of ovarian cancer in The Netherlands during the period 1975-1985: a registry-based study.

H R Balvert-Locht1, J W Coebergh, W C Hop, H A Brölmann, M Crommelin, D J van Wijck, M T Verhagen-Teulings.   

Abstract

Survival of 568 patients with ovarian cancer, diagnosed in 1975-1985, was studied by means of a population-based registry in the Southeast Netherlands. Patients diagnosed in the period 1981-1985 had a significantly better prognosis than patients diagnosed in 1975-1980. This improvement of survival declined with advancing age of the patients. In women younger than 60 years, mortality from ovarian cancer decreased, while incidence remained stable. Apart from the effect of new treatment methods, consisting of more extensive tumor reduction and cisplatin-based combination chemotherapy, advances in supportive care as well as a trend toward earlier diagnosis, possibly in combination with an increasing proportion of less malignant tumors, may explain the improvement in prognosis. Survival was strongly related to stage at diagnosis and to age, the prognosis of younger patients being more favorable. Patients with tumors of either germ cell or stromal origin generally survived longer than patients with epithelial tumors, but this difference disappeared after adjustment for stage and age. Patients still alive after 6 years did not have a survival significantly different from that of the general female population.

Entities:  

Mesh:

Year:  1991        PMID: 1916506     DOI: 10.1016/0090-8258(91)90222-q

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  7 in total

Review 1.  Platelet effects on ovarian cancer.

Authors:  Ashley N Davis; Vahid Afshar-Kharghan; Anil K Sood
Journal:  Semin Oncol       Date:  2014-04-23       Impact factor: 4.929

Review 2.  Anti-vascular therapies in ovarian cancer: moving beyond anti-VEGF approaches.

Authors:  Hyun-Jin Choi; Guillermo N Armaiz Pena; Sunila Pradeep; Min Soon Cho; Robert L Coleman; Anil K Sood
Journal:  Cancer Metastasis Rev       Date:  2015-03       Impact factor: 9.264

Review 3.  Beyond chemotherapy: targeted therapies in ovarian cancer.

Authors:  Timothy A Yap; Craig P Carden; Stan B Kaye
Journal:  Nat Rev Cancer       Date:  2009-03       Impact factor: 60.716

4.  Near-infrared fluorescent imaging of metastatic ovarian cancer using folate receptor-targeted high-density lipoprotein nanocarriers.

Authors:  Ian R Corbin; Kenneth K Ng; Lili Ding; Andrea Jurisicova; Gang Zheng
Journal:  Nanomedicine (Lond)       Date:  2012-10-15       Impact factor: 5.307

5.  The effect of neighborhood-level socioeconomic status on racial differences in ovarian cancer treatment in a population-based analysis in Chicago.

Authors:  Charlotte E Joslin; Katherine C Brewer; Faith G Davis; Kent Hoskins; Caryn E Peterson; Heather A Pauls
Journal:  Gynecol Oncol       Date:  2014-08-28       Impact factor: 5.482

6.  Genome wide DNA copy number analysis of serous type ovarian carcinomas identifies genetic markers predictive of clinical outcome.

Authors:  David A Engler; Sumeet Gupta; Whitfield B Growdon; Ronny I Drapkin; Mai Nitta; Petra A Sergent; Serena F Allred; Jenny Gross; Michael T Deavers; Wen-Lin Kuo; Beth Y Karlan; Bo R Rueda; Sandra Orsulic; David M Gershenson; Michael J Birrer; Joe W Gray; Gayatry Mohapatra
Journal:  PLoS One       Date:  2012-02-15       Impact factor: 3.240

7.  Management of ovarian cancer: referral to a multidisciplinary team matters.

Authors:  E J Junor; D J Hole; C R Gillis
Journal:  Br J Cancer       Date:  1994-08       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.